瑞士生物科技公司Oculis研发溶解纳米粒子技术，以非侵入方式治疗视网膜疾病 | 瑞士创新100强

Company Overview - Oculis is a Swiss biotechnology company founded in 2017, focusing on the development of dissolving nanoparticle technology for eye treatments [2] - The company was co-founded by Einar Stefánsson and Thorsteinn Loftsson, both of whom have extensive academic and professional backgrounds in ophthalmology and pharmaceutical chemistry [2] - Oculis is headquartered in Switzerland and operates in the United States, China, and Europe [2] Technology and Products - Oculis has developed a proprietary technology called OPTIREACH®, which enhances the delivery of eye drops to the back of the eye, improving treatment for various eye diseases [6] - The lead product, OCS-01, is a preservative-free eye drop formulation combining dexamethasone with OPTIREACH® technology, aimed at treating diabetic macular edema (DME) [6] - OCS-01 is currently in Phase 3 clinical trials, showing effectiveness in improving vision and reducing central macular thickness in patients with DME [6] Market Context - Diabetic macular edema affects approximately 37 million people globally, with projections to rise to 53 million by 2040 due to increasing diabetes prevalence [4] - Current treatments for DME are primarily invasive, often requiring frequent injections, which can be burdensome for patients [4] - Oculis's non-invasive approach with OCS-01 offers a more comfortable and convenient treatment option for millions of patients suffering from retinal diseases [6] Additional Pipeline Products - Besides OCS-01, Oculis is developing OCS-02, a topical anti-TNF-α monoclonal antibody fragment for dry eye treatment, currently in Phase 2b clinical studies [7] - OCS-05 is another product aimed at protecting nerve axons in acute optic neuritis and other neuro-ophthalmic diseases, currently undergoing clinical research in Europe [7] Financial and Market Position - Oculis went public on NASDAQ following a SPAC merger with European Biotech Acquisition Corp on March 3, 2023 [7] - The company raised $59 million in an oversubscribed private placement in April 2024 and secured an additional $100 million in February 2025 to accelerate product development [7] - Oculis was recognized in the 2022 TOP100 Swiss Startups list, highlighting its innovative potential and market prospects in the biotechnology sector [9]